A high-dose statin therapy for a post-acute coronary syndrome patient appears to produce no higher risk of kidney injury than a low-dose regimen. Study findings may reassure clinicians that high-potency statins are safe for patients after ACS. MedPage Today reports:
For post-acute coronary syndrome patients, high-dose statin therapy appeared to produce no higher a risk of kidney injury than a low-dose regimen, according to preliminary subanalyses of two randomized trials.
There were no differences between patients taking either 40 or 80 mg of a statin in creatinine elevations of >1.5, >2.0, and >3.0 mg/dL in the PROVE IT-TIMI 22 randomized trial, according to Amy Sarma, MD, MHS, of Brigham and Women's Hospital in Boston, and colleagues.
Similarly, in the A-to-Z Trial, researchers found no statistical differences in creatinine elevation at the same three increased levels between patients receiving 20 mg or 40 mg of statin therapy, Sarma reported during the American Heart Association's Emerging Science Series webinar.
Read the full story here: http://bit.ly/12ep1os